We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01620047
First Posted: June 15, 2012
Last Update Posted: November 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Tampa General Hospital
Information provided by (Responsible Party):
Enrico Camporesi, University of South Florida
  Purpose
Major surgery involving the knee is often associated with severe postoperative pain. Postoperative pain control remains a significant contributor to delayed recovery and length of hospital stay. Approaches to minimize postoperative pain after surgery are a matter of major concern due to the need for early mobilization, a crucial factor in good postoperative rehabilitation. Femoral nerve blocks by either continuous infusion or single injection of anesthetics provide an effective method for analgesia while minimizing the need for systemic opioid therapy, reducing the opioid induced side effects, and facilitating early ambulation. Administration of fentanyl has shown to be a highly effective method to control pain after Total Knee Replacement (TKR). The investigators hypothesize that fentanyl infusions will result in greater post-operative strength in the operative knee.

Condition Intervention
Total Knee Replacement Primary Knee Arthroplasty Drug: Fentanyl Drug: Ropivacaine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study

Resource links provided by NLM:


Further study details as provided by Enrico Camporesi, University of South Florida:

Primary Outcome Measures:
  • Comparison of Postoperative Strength (Extension) [ Time Frame: 24 hours post-surgery ]
    To assess extension force postoperatively to discern differences in muscle strength retention between continuous femoral nerve sheath catheter administration of fentanyl or Ropivacaine or a continuous IV infusion of fentanyl.


Secondary Outcome Measures:
  • VAS Scores and Postoperative Supplemental Morphine Consumption [ Time Frame: 24 hours post-surgery ]

    Secondary Objective

    • To determine the amount of required supplemental analgesia during the postoperative period.
    • To determine postoperative analgesia using a Visual Analog Scale (VAS) 0 - 10 centimeter line.

  • Serum Fentanyl Levels [ Time Frame: 24 hours post-surgery ]
    To identify a difference in serum fentanyl levels among the groups.


Enrollment: 60
Study Start Date: March 2011
Study Completion Date: March 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Femoral Nerve Fentanyl
Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Drug: Fentanyl
Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
Active Comparator: Femoral Nerve Ropivacaine
Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Drug: Ropivacaine
Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Placebo Comparator: Intravenous Fentanyl with placebo
Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Drug: Fentanyl
0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).

Detailed Description:
All subjects scheduled to receive a unilateral, primary total knee replacement were evaluated for eligibility in the preoperative anesthesia center. Adults, older than 18 years of age, ASA I-III were included in the study. Subjects who were either pregnant, on anticoagulant therapy, allergic to opioids, local anesthetics, chronic pain patients, history of traumatic lower extremity injury, or had a body mass index of greater than 35 kg/m2 were excluded from the study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing unilateral primary total knee replacement
  • ASA class I-III
  • 18 years and older

Exclusion Criteria:

  • Patient refusal
  • Pregnancy
  • Coagulopathy
  • Adverse/allergic reaction to any opioids or local anesthetics
  • History of long-term opioid use (greater than 60 days)
  • Infection
  • Traumatic lower extremity injury
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01620047


Locations
United States, Florida
Tampa General Hospital
Tampa, Florida, United States, 33606
Sponsors and Collaborators
University of South Florida
Tampa General Hospital
Investigators
Principal Investigator: Devanand Mangar, MD Florida Gulf-to-Bay Anesthesiology Associates LLC
  More Information

Additional Information:
Publications:
Responsible Party: Enrico Camporesi, President, University of South Florida
ClinicalTrials.gov Identifier: NCT01620047     History of Changes
Other Study ID Numbers: TGH-007 IRB # Pro00002055
First Submitted: June 12, 2012
First Posted: June 15, 2012
Results First Submitted: May 23, 2013
Results First Posted: November 11, 2013
Last Update Posted: November 11, 2013
Last Verified: September 2013

Keywords provided by Enrico Camporesi, University of South Florida:
Regional Anesthesia
Post-operative pain management
Femoral Nerve Block
Total Knee Replacement

Additional relevant MeSH terms:
Anesthetics
Fentanyl
Ropivacaine
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Opioid
Narcotics
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics, Local